These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 33664813)

  • 1. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
    Cao B; Wang P; Gu L; Liu J
    Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
    Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
    Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Zengin T; Önal-Süzek T
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmoglein 3 and Keratin 14 for Distinguishing Between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Dong Y; Li S; Sun X; Wang Y; Lu T; Wo Y; Leng X; Kong D; Jiao W
    Onco Targets Ther; 2020; 13():11111-11124. PubMed ID: 33149622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
    Liu T; Xu S; Liu X
    Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
    Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
    Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Patterns of mRNA and lncRNA Expression Differences Between Lung Squamous Cell Carcinoma and Adenocarcinoma.
    Tian Y; Yu M; Sun L; Liu L; Wang J; Hui K; Nan Q; Nie X; Ren Y; Ren X
    J Comput Biol; 2020 Jul; 27(7):1067-1078. PubMed ID: 31750732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
    Yang Y; Wang M; Liu B
    J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
    Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
    Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Key Genes and Signaling Pathways in Entrectinibresistant Non-small Cell Lung Cancer Using Bioinformatic Analysis and Experimental Verification.
    Chen X; Zhao X; Li D; Zha W
    Curr Med Chem; 2024 Aug; ():. PubMed ID: 39108112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
    Yu H; Pang Z; Li G; Gu T
    J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Wang J; Zhan X
    Front Immunol; 2021; 12():752643. PubMed ID: 34887858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrative bioinformatics analysis the clinical value of KMT5A in different subtypes of lung cancer.
    Liu S; Tian W; Li B
    Comput Biol Chem; 2022 Feb; 96():107603. PubMed ID: 34894606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
    Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
    BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioinformatics analyses of the differences between lung adenocarcinoma and squamous cell carcinoma using The Cancer Genome Atlas expression data.
    Sun F; Yang X; Jin Y; Chen L; Wang L; Shi M; Zhan C; Shi Y; Wang Q
    Mol Med Rep; 2017 Jul; 16(1):609-616. PubMed ID: 28560415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of the key genes and characterizations of Tumor Immune Microenvironment in Lung Adenocarcinoma (LUAD) and Lung Squamous Cell Carcinoma (LUSC).
    Zhang L; Chen J; Cheng T; Yang H; Li H; Pan C
    J Cancer; 2020; 11(17):4965-4979. PubMed ID: 32742444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. System analysis of
    Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
    Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
    Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
    Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
    Li N; Li Y; Zheng P; Zhan X
    Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
    Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
    EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.